PDS Biotechnology Corp Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for the quarter ending 2021-12-31 was $16.00.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for the quarter ending 2021-09-30 was $0.00.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for the quarter ending 2021-03-31 was $35.75K, a 264.77% increase year-over-year.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for fiscal 2021 was $35.75K, a 79.03% increase from fiscal 2020.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for fiscal 2020 was $19.97K, a 46.15% decline from fiscal 2019.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for fiscal 2019 was $37.08K, a 74.46% decline from fiscal 2018.
- PDS Biotechnology Corp stock issued during period, value, employee benefit plan for fiscal 2018 was $145.17K, a 33.27% decline from fiscal 2017.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2021-12-31 | $16.00 10-K · filed 2023-03-28 | $35.75K 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $35.75K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $0.00 10-K · filed 2023-03-28 | $35.75K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $35.75K 10-K · filed 2023-03-28 | $45.91K derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $19.97K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-13 | $27.34K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $10.17K 10-Q · filed 2021-08-12 | $31.80K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $9.80K 10-Q · filed 2021-05-13 | $46.88K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $7.38K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $37.08K 10-K · filed 2021-03-18 |
| 2019-09-30 | $4.46K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $25.24K 10-Q · filed 2019-08-01 | |
| 2018-12-31 | $145.17K 10-K · filed 2019-02-21 | |
| 2017-12-31 | $217.54K 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |